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Abstract
Introduction: Both indole-3-carbinol and dietary lignans have beneficial effects on estrogen metabolism and breast cancer risk. There is 
no published literature on the effects of a combination product. This study was designed to investigate the impact of a combination   product 
on estrogen metabolism. The major trial objective was to determine whether a breast health supplement containing indole-3-carbinol 
and hydroxymatairesinol lignan would alter estrogen metabolism to favour C-2 hydroxylation and reduce C-16 hydroxylation. Higher 
concentrations of C-2 metabolites and lower concentrations of C-16 metabolites may reduce breast cancer risk and risk for other 
hormonally-related cancers.
Methods: Forty-seven pre-menopausal and forty-nine post-menopausal women were recruited for this study, and were divided by 
  random allocation into treatment and placebo group. The treatment supplement contained HMR lignan, indole-3-carbinol, calcium 
glucarate, milk thistle, Schisandra chinesis and stinging nettle, and each woman consumed either treatment or placebo for 28 days. At 
day 0 and day 28, blood samples were analysed for serum enterolactone concentrations, and first morning random urine samples were 
assessed for estrogen metabolites. Repeated measures ANOVA statistical testing was performed.
Results:  In  pre-menopausal  women,  treatment  supplementation  resulted  in  a  significant  increase  (P  ,  0.05)  in  urinary  2-OHE 
  concentrations and in the 2:16α-OHE ratio. In post-menopausal women, treatment supplementation resulted in a significant increase in 
urinary 2-OHE concentrations. In pre- and post-menopausal women combined, treatment supplementation produced a   significant increase 
in urinary 2-OHE concentration and a trend (P = 0.074) toward an increased 2:16α-OHE ratio. There were no significant increases in 
serum enterolactone concentrations in the treatment or placebo groups.
Conclusions:  Supplementation  with  a  mixture  of  indole-3-carbinol  and  HMR  lignan  in  women  significantly  increased  estrogen 
C-2 hydroxylation. This may constitute a mechanism for the reduction of breast cancer risk as well as risk for other estrogen-related 
cancers. Further studies with higher numbers of subjects are indicated.
Trial registration: ClinicalTrials.gov registration #NCT01089049.
Keywords: herbal supplement, breast health, estrogen metabolitesLaidlaw et al
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Introduction
The  relationship  between  breast  cancer  risk  and 
  concentrations of specific urinary estrogen metabolites 
is  well-established.1–8  Figure  1  illustrates  estrogen 
Phase 1 metabolic pathways.9 Estradiol and estrone 
are  interconvertible.  Both  are  metabolized  by 
  cytochrome P450 isoenzymes to hydroxylated metab-
olites and excreted in the urine or bile.3 Lord et al.3 
and others4–7 have suggested that the relative amounts 
of these metabolites influence risk for breast cancer 
and other estrogen-related cancers. C-2 hydroxyla-
tion  metabolites  2-hydroxyestrone  (2-OHE1)  and 
  2-hydroxyestradiol (2-OHE2) tend to be either weakly 
estrogenic or possibly anti-estrogenic.
The metabolite 16α-hydroxyestrone (16α-OHE1) 
binds covalently and irreversibly to the estrogen recep-
tor and is an endogenous carcinogen. The metabolites 
4-hydroxyestrone (4-OHE1) and 4-hydroxyestradiol 
(4-OHE2)  bind  to  DNA,  forming  semi-quinones 
that cause mutations which result in carcinogenesis, 
although they are present in much smaller concentra-
tions than 16α-OHE1.3,4,8
The roles of dietary lignans, normally found in 
the diet from whole grain and fruits and   vegetable 
sources, and of indole-3 carbinol (I3C), most often 
sourced dietarily from cruciferous vegetables, have 
received  increasing  attention  in  the  modulation 
of  breast  cancer  risk.  Evidence  for  their  meta-
bolic  effects  on  estrogen  elimination  pathways  is 
  emerging,  in  both  epidemiological  studies,  and  in 
clinical    trials  using  either  source  foods  or  derived 
supplements (10–22). The primary acid condensation 
product of I3C,   diindolylmethane (DIM) induces the 
  cytochrome P450 enzyme CYP1A1, which increases 
the   2-hydroxylation of estrogens.13,20
The  effects  of  lignan  consumption  are  influenced 
by  enzyme  genotypes,  specifically  catechol-O- 
methyltransfrase (COMT), required for the conversion   
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Figure 1. Metabolism of estrogen. Reprinted from Cancer letters, 211, Takahashi M, Shimomoto T, Miyajima K, et al., effects of estrogens and metabolites 
on endometrial carcinogenesis in young adult mice initiated with N-ethyl-N1-nitro-N-nitroguanidine, 1-9, Copyright (2004) with permission from elsevier.Breast health herbal formula supplement and estrogen metabolism
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of 4-OHE1 to its proliferative form (catechol estrogen-
3,4- quinones) and cytochrome P451 enzyme CYP1B1, 
needed in the conversion of estrogens to 16α-OHE1.8 
The  ratio  of  2-OHE  to  16α-OHE1  increased  with 
lignan consumption, and correlated directly with the 
number of variant alleles for COMT and for CYP1B1.22 
A lignan source derived from the   Norwegian spruce 
tree, 7-  hydroxymatairesinol (HMR lignan) had anti-
tumor effects in rat mammary cancers, and positively 
influenced the concentration of 2-OHE and the ratio 
of 2-OHE : 16α-OHE1 in human clinical trials.23,24
The purpose of this study was to determine the 
effects of supplementation the diets of women (not 
taking hormonal supplements or oral contraceptives) 
with an encapsulated combination of I3C and HMR 
lignan on urinary concentrations of 2-OHE and 16α-
OHE, on the ratio of 2-OHE to 16α-OHE, and on 
concentrations of serum enterolactone.
subjects and Methods
Subjects
Pre- and post-menopausal women were recruited for 
the trial through local newspaper advertising. Prior to 
their first lab visit, subjects underwent a telephone 
interview to assess their eligibility for the study, and 
to determine the current stage of their menstrual cycle. 
For pre-menopausal women, lab appointments were 
booked based on timing each subject’s first lab visit at 
the mid-point of the follicular phase of her menstrual 
cycle. After pre-screening and exclusion for use of 
any type of sex hormone supplementation (estrogen, 
progesterone,  androgens,  hormonal  oral  contracep-
tives),  and  for  a  family  history  of  breast  cancer, 
48 healthy pre-menopausal women aged 19 to 54, and 
50 healthy post-menopausal women aged 46 to 70 
were recruited for the study. Besides the use of hor-
mones,  exclusion  criteria  included  being  less  than 
18 years of age, pre-existence of any serious illness 
including fibrocystic breast disease or family history 
of ovarian cancer, and pregnancy or lactation.
Supplements
Supplements were encapsulated in vegetarian softgel 
white capsules, and each treatment capsule contained 
200 mg I3C and 10 mg HMR lignans, in accordance 
with  previous  research.14,24  Minor  constituents 
included 100 mg Milk Thistle [Silybum marianum], 
75  mg  calcium-D-glucarate,  75  mg  Schisandra 
chinesis, 50 mg Stinging Nettle Root [Urtica   dioica] 
and  10  mcg  vitamin  D.  The  placebo  consisted  of 
microcrystalline cellulose, and the daily dosage was 2 
capsules, one to be taken with breakfast and one with 
dinner.  The  supplements,  including  encapsulation, 
were  provided  by  Fem  Med  (Fem  Med  Formulas 
  Limited  Partnership,  Toronto,  Canada).  Both  the 
  clinical coordinator and trial participants were blinded 
to the type of supplement.
Study design
The  trial  was  a  double-blind,  placebo-controlled, 
parallel study in which 98 subjects were recruited to 
one of two arms of the study. One arm consisted of 
pre-menopausal  women  not  using  hormonal 
contraceptives,  while  the  other  consisted  of  post-
menopausal women not receiving HRT. Each arm of 
the study was carried out concurrently and in one 
phase, with no washout period. Subjects in each arm 
were randomly allocated to consume either the treat-
ment or a placebo for a period of 28 days. The ran-
domization  list  was  generated  using  an  internet 
program from Tufts University and the procedure was 
verified  using  SAS™  software  (http://www.tufts.
edu/∼gdallal/random_block_size.htm).
Duplicate measures of sitting blood pressure were 
measured using an automated digital blood   pressure 
device. Height and weight were measured in duplicate, 
and  Body  Mass  Index  (BMI)  calculated  using  the 
equation BMI = weight in kg/height in metres squared. 
Blood samples and first morning urine samples were 
collected from each group at day 0 and day 28, and 
adverse events diaries, for the recording of possible 
side-effects, were distributed to all subjects.
This study has been reviewed and approved by 
the Canadian Shield Ethics Review Board [CSERB], 
with  tracking  #08-10-001.  All  of  the  procedures 
followed throughout this study were in accordance 
with  the    Declaration  of  Helsinki,  and  followed 
the  International  Conference  on  Harmonisation 
(ICH)/World  Health  Organisation  (WHO)  Good 
  Clinical  Practice    standards  for  clinical  trials.  The 
study  was  also  reviewed  and  approved  by  Health 
Canada’s   Natural Health Products Directorate (File 
#137987). All subjects signed an Informed Consent 
document that followed ICH guidelines and had been 
approved  by  the  CSERB  and  by  Health  Canada’s 
Natural Health Products Directorate.Laidlaw et al
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Laboratory analyses
First morning urine samples were collected, aliquoted 
into cryovials and stored at −80 °C until analyzed. 
They were analysed for creatinine concentration using 
a colourimetric detection ELISA methodology (Assay 
Designs, Ann Arbor, MI), and for estrogen metabo-
lites,  including  2-OHE1,  2OHE2  and  16α-OHE1 
concentrations using stable isotope dilution gas chro-
matography-mass spectrometry.25 Estrogen metabo-
lites were calculated as ng per mg of creatinine, in 
order to standardise the results and facilitate compari-
sons between participants. Blood samples were col-
lected by venipuncture into evacuated tubes with no 
anti-coagulant. After allowing time for the blood to 
clot, tubes were centrifuged at 3,200 rpm for 10 min-
utes at 25 °C. Serum supernatant was portioned into 
cryovials and stored at −80 °C until analysed for con-
centrations of serum enterolactone using gas chroma-
tography-mass spectrometry.26
Statistical analyses
Statistical analyses were performed using SAS soft-
ware (version 9.1; SAS Institute, Cary, NC). ANOVA 
for  repeated  sampling  was  used  to  compare  the 
treatment group with the placebo group, after pooling 
of the pre- and post-menopausal treatment and pla-
cebo group results. Additionally, each treatment sub-
group, ie, post-menopausal women without HRT, and 
pre-menopausal  women  not  using  hormonal 
contraceptives, was compared with its corresponding 
placebo  group,  again  using  ANOVA  for  repeated 
  sampling.  A  power  analysis  to  determine  the 
  appropriate number of subjects was carried out, using 
known urinary estrogen metabolite variability. For a 
two-tailed α level of 0.05 (P-value for statistical sig-
nificance), and a β level of 80% (desired power), it 
was estimated that a minimum of 44 subjects would 
be required in order to detect a minimum change of 
0.3 ng/mg creatinine in estrogen metabolite concen-
tration. To allow for drop-outs/attrition, a number of 
48  was  deemed  appropriate.  All  of  the  statistical 
analyses were performed by an independent Ph.D. in 
biostatistics and Senior Analyst at the University of 
Guelph, Ontario, Canada.
Results
Although a total of 98 pre- and post-menopausal women 
were initially recruited, the number of subjects whose 
data was statistically analysed was 68. Table 1 illustrates 
the reasons for this reduction in numbers. A creatinine 
level  of  #0.20  mg  is  very  low  for  a  first  morning 
sample, and indicates the possibility of a missed first 
morning sample and/or middle-of-the-night uncollected 
bladder evacuation. Nonetheless, it results in very dilute 
and probably inaccurate measurements of the estrogen 
biomarkers of interest; hence samples with creatinine 
levels of #0.20 mg were omitted from the data base. If 
the capsule count indicated an intake of ,85% over the 
previous 28 days, subjects were assumed to be non-
compliant, and their data was omitted.
The  baseline  characteristics  of  the  subjects  are 
presented in Table 2, and include data for all sub-
jects enrolled in the trial, excluding the subject who 
was  unable  to  give  blood,  and  the  early  drop-out. 
The range in age for the pre-menopausal women was 
19 to 54 years, and for post-menopausal women it 
was 46–70 years. Not unexpectedly, blood   pressure 
  measurements  for  post-menopausal  (older)  women 
Table 1. Subject numbers and reasons for data removal.
pre-menopausal women # post-menopausal women #
initial total 48 initial total 50
1 blood sampling inability  47 1 side-effects drop-out  49
1 urine sample result missing 46 12 very low creatinine levels1  37
1 very low creatinine level  45 1 nd2 urine sample for 2-Ohe  36
2 nd urine samples for 2-Ohe  43 5 nd urine samples for 16α-Ohe  31
1 nd urine sample for 16α-Ohe 42 1 non-compliant3 subject 30
4 non-compliant subject 38 TOTAL 30
TOTAL 38
Total for both pre- and post-menopausal women: 68
notes: 1#0.20 mg creatinine; 2nd = non-detected; 3Capsule count ,85%.Breast health herbal formula supplement and estrogen metabolism
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tended  to  be  somewhat  higher  than  those  for 
  pre-menopausal (younger) women, given that blood 
pressure tends to increase with age.
Results for estrogen metabolite concentrations for 
pre- and post-menopausal women combined are pre-
sented in Table 3. For the treatment group, the mean 
change in concentration of 2-OHE was highly signifi-
cant, and there was a trend towards an increase in the 
mean ratio of 2-OHE to 16α-OHE. Statistically, 16α-
OHE concentrations were unchanged in both groups. 
None of the concentrations of the biomarkers of inter-
est were significantly changed in the placebo group.
Table  4  lists  estrogen  metabolite  concentrations 
for  the  pre-menopausal  group.  In  pre-menopausal 
women,  both  the  mean  2-OHE  concentration  and 
the mean ratio of 2-OHE to 16α-OHE1 were sig-
nificantly increased in the treatment group. None of 
these biomarker concentrations significantly changed 
in the placebo group, nor was the mean concentration 
of 16α-OHE.
For post-menopausal women, the results are pre-
sented in Table 5. Only the mean 2-OHE concentration 
was significantly increased in the post-menopausal 
treatment  group.  In  this  group,  the  mean  concen-
tration of 16α-OHE was very close to significance 
(P  =  0.057),  and  the  mean  ratio  change  was  not 
  significant. None of the placebo biomarkers exhibited 
any significant change in mean concentration.
Although  4-OHE  was  not  identified  as  a  bio-
marker  of  specific  interest  in  this  trial,  it  has 
been    recognised  as  a  cell  proliferator  similar  to 
16α-OHE,3,4,8 and results for 4-OHE were   available 
from the estrogen metabolite analyses. There were 
fewer 4-OHE values for statistical analysis, because 
several  of  the  subjects’  4-OHE  concentrations 
were non-detectable. The results that are   available 
are  presented  in  Table  6.  In  the  pre-menopausal 
group,  both  the  treatment  and  the  placebo  group 
exhibited a reduction in mean 4-OHE concentration, 
though neither reduction was statistically   significant. 
In  post-menopausal  women,  the  placebo  group 
increased  the  mean  4-OHE  concentration,  from 
2.46  to  4.75  ng/mg  creatinine,  while  the  treat-
ment group decreased 4-OHE concentration from 
7.49 to 4.70 ng/mg creatinine. Neither result was 
statistically significantly; however, only 10 and 12 
Table 2. Demographic and anthropometric data for participants at baseline (mean ± SD).
Group  pre-menopausal women post-menopausal women
placebo Treatment placebo Treatment
n 17 21 13 17
Age (years) 38 ± 10 36 ± 9 56 ± 6 57 ± 6
Weight (kg) 77.8 ± 24.3 75.5 ± 17.5 78.7 ± 19.0 67.2 ± 13.0
BMi (kg/m2) 27.82 ± 8.87 26.83 ± 6.04 30.03 ± 7.18 25.66 ± 4.30
Blood pressure 
(mmhg)
112/74 ± 12/11 110/75 ± 14/11 118/81 ± 12/11 121/79 ± 20/13
Table 3. Comparison of day 0 vs. day 28 concentrations of urinary biomarkers of interest for pre- and post-menopausal 
women consuming the treatment or a placebo.
Biomarker pre- and post-menopausal women n = 68
ng/mg creatinine Treatment n = 38 placebo n = 30
Day 0 Day 28 P-value Day 0 Day 28 P-value
2-Ohe 1 + 2 Mean 7.63 15.11 0.001 9.77 11.13 0.524
SD1 8.31 17.50 11.5 9.64
16α-Ohe Mean 5.46 6.50 0.082 6.05 5.66 0.620
SD 4.50 5.07 4.76 3.93
2:16α-Ohe  
ratio
Mean 2.52 3.33 0.074 2.17 2.70 0.451
SD 3.70 3.78 2.95 3.46
Abbreviation: 1SD, standard deviation.Laidlaw et al
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4-OHE results were available for post-menopausal 
placebo and treatment groups, respectively.
In order to further elucidate this data, a ratio of 
“pro-carcinogenic” and “anti-carcinogenic” metabo-
lites was devised. The numerator consisted of 4-OHE 
(1 and 2), 16α-OHE1 and estriol (E3), and the denom-
inator was 2-OHE (1 and 2). E3 was included in the 
numerator  because  it  is  the  product  of  16α-OHE 
hydroxylation,  and  has  itself,  along  with  its  other 
metabolites, been implicated in possible carcinogenic 
activity, in animal models.25 Non-detectable levels of 
E3, added to non-detectable levels of 2-OHE and/or 
4-OHE and/or 16α-OHE, resulted in the number of 
subjects in this analysis being quite small. Table 7 
illustrates these ratios. Because of the small number 
of subjects, it is difficult to draw conclusions from this 
table. Nonetheless, in the treatment group, there was a 
highly significant reduction the carcinogenic ratio for 
all women, a significant reduction in this ratio for the 
pre-menopausal women, and a trend towards a signif-
icant reduction in this ratio for the post-menopausal 
group (P = 0.067 for the latter). However, the reduction 
in this ratio for the pre-  menopausal placebo group 
was almost identical to that of the pre-menopausal 
treatment group, and the lack of significance in the 
former was undoubtedly due to the smaller number of 
subjects (10 vs. 19, respectively).
Serum  enterolactone  concentrations  for  the 
whole group and the two subgroups are presented in 
Table 8. There were no differences among any of the 
groups  or  subgroups  in  mean  serum  enterolactone 
concentrations.
Adverse  events  were  collated  from  diaries  that 
study subjects completed as needed. There were more 
adverse events reported in the treatment group than 
in the placebo group. Of 47 adverse events   diaries 
received  from  pre-menopausal  women,  21  noted 
adverse events, 14 in the treatment group and 7 in the 
placebo group. By far, the most common adverse event 
reported was headache (20 incidences in the treatment 
group, 8 in the placebo group) with stomach pain as 
the second most common event (14 in the treatment 
group), and single occurrences of other minor adverse 
events such as nausea, irritability, rash. Of 50 adverse 
Table 4. Comparison of day 0 vs. day 28 concentrations of urinary biomarkers of interest for pre-menopausal women 
  consuming the treatment or a placebo.
Biomarker pre-menopausal women n = 38
ng/mg creatinine Treatment n = 21 placebo n = 17
Day 0 Day 28 P-value Day 0 Day 28 P-value
2-Ohe  Mean 6.34 13.29 0.003 9.37 10.5 0.667
SD1 7.01 14.05 11.4 8.42
16α-Ohe Mean 7.69 8.58 0.380 7.38 7.01 0.817
SD 4.66 5.64 5.28 4.52
2:16α-Ohe  
ratio
Mean 0.88 1.66 0.016 1.39 1.62 0.444
SD 0.74 1.27 1.17 1.01
Abbreviation: 1SD, standard deviation.
Table 5. Comparison of day 0 vs. day 28 concentrations of urinary biomarkers of interest, for post-menopausal women 
consuming the treatment or a placebo.
Biomarker post-menopausal women n = 30
ng/mg creatinine Treatment n = 17 placebo n = 13
Day 0 Day 28 P-value Day 0 Day 28 P-value
2-Ohe  Mean 9.22 17.37 0.035 10.29 11.9 0.656
SD1 9.67 21.27 11.99 11.4
16α-Ohe Mean 2.70 3.92 0.057 4.30 3.79 0.556
SD 2.23 2.63 3.43 1.81
2:16α-Ohe  
ratio
Mean 4.54 5.40 0.387 3.20 4.13 0.570
SD 4.81 4.77 4.14 4.87
Abbreviation: 1SD, standard deviation.Breast health herbal formula supplement and estrogen metabolism
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events diaries received from post-menopausal women, 
13 noted adverse events, 10 in the treatment group 
and 3 in the placebo group. Again, the most common 
adverse event reported was headache (11 incidences 
in the treatment group, 6 in the placebo group), as 
well as 2 incidences of heartburn reported in the treat-
ment group and 4 incidences of jaw pain reported in 
the placebo group.
Discussion
For  pre-menopausal  women,  these  results    suggest 
that consumption of a daily dosage of 2 capsules of 
the treatment offers beneficial outcomes, in that the 
mean  2-OHE  concentration  and  the  mean 
2-OHE:16α-OHE ratio significantly increased   during 
a 28-day supplementation. In contrast, there were no 
significant  differences  in  the  placebo  group.  The 
estrogen metabolite 2-OHE2 undergoes conjugation 
to 2-methoxyestradiol (2-MeO-E2), which has been 
shown  to  inhibit  cell  proliferation.27  This  2-OHE2 
conjugation product has also been identified as an 
inhibitor of angiogenesis and tumour growth; thus, an 
increase in 2-OHE concentration, and the subsequent 
increase  in  2-MeO-E2,  is  considered  a  beneficial 
outcome  independent  of  the  2-OHE:16α-OHE 
ratio.28–80  The  increased  ratio,  having  been  clearly 
identified as a biomarker of a reduction in breast can-
cer risk in   pre-menopausal women,2,5,31 is a very posi-
tive  outcome,  and  an  outcome  that  has  previously 
been  observed  in  pre-menopausal  women  taking 
either I3C or dietary lignans.10,12,14
For  post-menopausal  women,  the  results  are 
more complex. There was a significant increase in 
the concentration of 2-OHE from day 0 to day 28 in 
the treatment group, but not in the placebo group. 
As  with  pre-menopausal  women,  this  represents  a 
  significant beneficial effect, because previous research 
has indicated that an increase in the concentration of 
2-OHE in the urine is correlated independently with 
a  reduction  in  breast  cancer  risk.28–30  Furthermore, 
this metabolite is regarded as a weak estrogen, with 
minimal negative effects, and possibly anti-estrogenic 
effects, compared to the much more potent negative 
effects of 16α-OHE.3
Table 6. Comparison of day 0 vs. day 28 concentrations of urinary 4-Ohe, for pre- and post-menopausal women   consuming 
the treatment or a placebo (mean and SD).
Treatment  placebo
Day 0 Day 28 P-value n Day 0 Day 28 P-value n
All women  4.10 2.91 0.158 32 3.42 2.95 0.750 25
SD 6.94 3.73 5.35 4.72
Pre-menopausal 
women
2.05 1.37 0.307 20 3.95 1.60 0.146 15
SD 3.08 1.10 6.61 1.41
Post-menopausal 
women
7.49 4.70 0.321 12 2.46 4.75 0.393 10
SD 9.57 4.78 2.53 6.67
Table 7. Comparison of day 0 vs. day 28 concentrations of calculated carcinogenic ratios, for pre- and post-menopausal 
women consuming the treatment or a placebo (mean and SD).
Treatment placebo
Day 0 Day 28 P-value n Day 0 Day 28 P-value n
All women  4.91 2.12 0.005 26 3.58 3.40 0.881 17
SD 5.02 1.76 4.22 6.26
Pre-menopausal 
women 
3.90 2.08 0.031 19 3.59 1.64 0.121 10
SD 3.38 1.82 3.85 1.00
Post-menopausal 
women 
7.64 2.22 0.067 7 3.55 5.93 0.231 7
SD 7.66 1.69 5.03 9.51Laidlaw et al
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Given the expectation that there is a limited pool of 
estrogen substrates for the various metabolic pathways, 
one would expect that an increase in the activity of 
the pathway producing 2-OHE would concomitantly 
result in a reduction in the activity of the 16α-OHE 
pathway,  and  this  was  the  hypothesis  confirmed 
in  an  IC3  supplementation  trial.32  In  another  I3C 
supplementation trial, the authors noted that although 
a significant increase in the 2:16 ratio was observed, 
3 of 20 subjects experienced no change in this ratio at 
any time-point.10 They noted that “ … some individu-
als may be resistant to change”. In our study, 4 of 21 
pre-menopausal and 5 of 17 post-menopausal women 
experienced a decrease in this ratio. In a study on 
soy consumption in post-menopausal women, only 
women who were equol producers increased the 2:16 
ratio.33 It may be that future nutrigenomic studies may 
elucidate genetic differences in the way some women 
metabolize  estrogen,  and/or  in  how  they  digest, 
absorb and metabolize dietary components that influ-
ence estrogen metabolism.
For the combined results in both pre- and post-
menopausal women, the increase in 2-OHE in the 
treatment  group  was  highly  significant,  and  there 
was a trend towards significance in the 2:16a-OHE 
ratio. The unexpected trend towards an increase in 
the concentration of 16α-OHE in both the pre- and 
post-menopausal  groups  undoubtedly  attenuated 
what might have been a significant increase in the 
2-OHE:16α-OHE ratio when the results for both pre- 
and  post-menopausal  women  were  combined.  The 
P-value for the 2:16 ratio, in the combined groups, 
was 0.074, and this is most likely a combination of 
the significant pre-menopausal P-value of 0.016, and 
the non-significant post-menopausal P-value of 0.387. 
However,  the  small  increase  in  average    levels  of 
16α-OHE in both pre- and post-menopausal women 
needs to be investigated further, to assess whether 
this is a spurious finding or the result of metabolic 
alterations  in  estrogen  metabolism.  This  estrogen 
metabolite is associated with an increase in breast 
cancer risk;1–7 thus, any supplement that appears to 
increase the level of this metabolite requires further 
investigation.
The  analyses  of  4-OHE  and  the  so-called 
carcinogenic  ratio  provided  somewhat  interest-
ing  results.  Although  there  were  no  significant 
  differences  in  4-OHE1  concentrations  among  any 
of the groups or sub-groups, the apparent reduction 
in 4-OHE levels in the treatment group, with only 
12 subjects, in comparison with an increase in 4-OHE 
levels in the placebo group of 10 subjects, warrants 
further  research,  although  a  larger  trial  may  show 
these results to be extraneous. The carcinogenic ratio, 
which combines E3, 4-OHE (1 and 2), 16α-OHE1 and 
2-OHE (1 and 2) provided more interesting results, 
given the significant or close-to-significant results for 
the treatment groups and lack thereof in the placebo 
groups.
Although  there  may  be  dispute  as  to  whether 
E3  belongs  among  the  carcinogenic  metabolites, 
Takahashi  et al.9 reported on the carcinogenic effects 
of estriol and its metabolites in young adult mice. 
After  initiation  of  endometrial  carcinogenesis  with 
N-ethyl-N1-nitro-N-nitroguanidine,  the  researchers 
measured the incidences of endometrial hyperplasia/
proliferative lesions and adenocarcinomas following 
implantation  with  estrogen  metabolite  pellets.  The 
metabolites  that  produced  significant  incidences  of 
proliferative lesions were 2-hydroxyestriol (2-OH-E3), 
Table 8. Mean serum enterolactone concentrations for day 0 and day 28 in the treatment and placebo groups, for pre- and 
post-menopausal women together and separately.
Group Day 0 Day 28
Average sD1 Average sD
All women Treatment n = 38 5.0 5.9 4.9 7.1
Placebo n = 30 3.6 3.0 4.0 5.7
Pre-menopausal women Treatment n = 21 4.2 5.0 4.2 7.8
Placebo n = 17 4.2 3.4 5.3 7.4
Post-menopausal women Treatment n = 17 6.1 6.8 5.8 6.2
Placebo n = 13 2.9 2.4 2.4 1.1
Abbreviation: 1SD, standard deviation.Breast health herbal formula supplement and estrogen metabolism
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2-methoxyestriol  (2-MeO-E3),  2-  methoxyestradiol 
(2-MeO-E2) and 16-epiestriol, and those that resulted 
in adenocarcinomas were estrone (E1), estradiol (E2), 
E3, 16α-OHE1, 16β-OHE1 and 17-epiestriol (a metab-
olite of 16α-OHE1). In effect, two estriol metabolites 
produced lesions, and two produced adenocarcinomas. 
Human studies are less definitive, but there is some 
evidence that estriol metabolites may be carcinogenic 
in some instances.34
In this trial, it was expected that serum entero-
lactone concentrations would rise as dietary HMR 
lignan intake rose. The fact that there were no sig-
nificant increases in the average serum enterolactone 
concentrations in any of the groups or sub-groups is 
puzzling. Originally, the manufacturer of this specific 
lignan (Linnea, Inc., Switzerland) stated, in a brochure 
for  public  consumption,  that  a  significant  increase 
in  serum  enterolactone  concentration  may  only  be 
expected if dietary intake of HMR lignans is 25 to 
50 mg/day.35 However, a later brochure indicated that 
10 to 50 mg/day would be sufficient to increase serum 
enterolactone concentrations,36 and this was based on 
a study by Cosentino.37 The daily intake of HMR lig-
nan in this trial was 20 mg, and this may or may not 
have been sufficient to see a significant increase in 
serum enterolactone concentrations. Further research 
on the most efficacious dosage of HMR lignans is 
warranted. Serum quantification of the HMR lignin 
metabolite 7-hydroxy-HMR lignin and the enterolac-
tone precursor enterodiol would also be advisable, in 
order to verify adequate HMR lignan absorption and 
metabolism.
Although it was determined, by power analysis, 
that 44 subjects per group would be needed in order 
to obtain statistically robust results, the unexpected 
reduction in group numbers to 38 women consuming 
the treatment and 30 women consuming the   placebo 
attenuated  the  number  and  power  of    statistical 
findings. These findings were further attenuated when 
the treatment and placebo groups were   subdivided 
into  pre-  and  post-menopausal  women,  and  when 
non-  detectable concentrations of other metabolites of 
interest, such as 4-OHE, were analysed statistically. 
Thus,  the  fact  that  several  statistically-significant 
results were obtained with only 21 pre-menopausal 
women in the treatment group, and 17 post-  menopausal 
women in the treatment group, for the major metabo-
lites, and even fewer for other metabolites, indicates 
that  these  findings  are  important,  and  that  future 
research with a greater number of participants, ie, 
sufficient to subdivide into pre- and post-menopausal 
groups  while  retaining  statistical  robustness,  may 
well elicit more favourable results.
conclusions
In pre-menopausal women, consumption of a specific 
mixture of I3C and HMR lignan increased the mean 
urinary  concentration  of  the  estrogen  metabolite 
2-OHE and the mean urinary ratio of 2-OHE:16α-
OHE, and this may reduce breast cancer risk. In post-
menopausal  women,  consumption  of  a  specific 
mixture of I3C and HMR lignan increased the mean 
urinary  concentration  of  the  estrogen  metabolite 
2-OHE, and this may reduce breast cancer risk. How-
ever, the evidence for this is weaker than for pre-
menopausal  women  because  the  2-OHE:16α-OHE 
ratio did not increase significantly in this group.
In their 2002 review article, Lord  et al. noted that 
the maximum 2:16 OHE ratio one could safely strive 
towards  without  encountering  undesirable  adverse 
effects (such as an increase in osteoporosis) would 
be 8.0. In our trial, where the daily supplement dose 
was  400  mg  I3C,  the  average  maximum  ratio  we 
achieved was 5.4, and this was in post-menopausal 
women. For the pre-menopausal women, there was a 
110% increase in the average urinary 2-OHE concen-
tration, and a 100% increase in the 2:16 OHE ratio, 
while  these  numbers  for  post-menopausal  women 
were 88% and 19%, respectively. Except for the post-
menopausal 2:16 ratio reduction, these results com-
pare favourably with other trial results, where 2-OHE 
levels increased by 50%,38 and 2:16 ratio increased 
by 66%.14 It also resulted in a Relative Risk reduc-
tion of breast cancer risk from 1.00 to 0.763 in pre-
menopausal women.
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